MA47398A - Immunothérapie à base de vecteurs d'administration personnalisés et utilisations associées - Google Patents
Immunothérapie à base de vecteurs d'administration personnalisés et utilisations associéesInfo
- Publication number
- MA47398A MA47398A MA047398A MA47398A MA47398A MA 47398 A MA47398 A MA 47398A MA 047398 A MA047398 A MA 047398A MA 47398 A MA47398 A MA 47398A MA 47398 A MA47398 A MA 47398A
- Authority
- MA
- Morocco
- Prior art keywords
- immunotherapy based
- associated uses
- personalized administration
- administration vectors
- vectors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Marine Sciences & Fisheries (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662287871P | 2016-01-27 | 2016-01-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA47398A true MA47398A (fr) | 2019-12-11 |
Family
ID=59398812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA047398A MA47398A (fr) | 2016-01-27 | 2017-01-27 | Immunothérapie à base de vecteurs d'administration personnalisés et utilisations associées |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20190032064A1 (fr) |
| EP (1) | EP3408395A4 (fr) |
| JP (1) | JP2019503186A (fr) |
| KR (1) | KR20180100443A (fr) |
| CN (1) | CN108884468A (fr) |
| AU (1) | AU2017211387A1 (fr) |
| CA (1) | CA3012829A1 (fr) |
| MA (1) | MA47398A (fr) |
| MX (1) | MX2018009225A (fr) |
| SG (1) | SG11201806392XA (fr) |
| WO (1) | WO2017132547A1 (fr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9012141B2 (en) | 2000-03-27 | 2015-04-21 | Advaxis, Inc. | Compositions and methods comprising KLK3 of FOLH1 antigen |
| WO2012125551A1 (fr) | 2011-03-11 | 2012-09-20 | Advaxis | Adjuvants à base de listeria |
| SG10201700392UA (en) | 2012-03-12 | 2017-03-30 | Advaxis Inc | Suppressor cell function inhibition following listeria vaccine treatment |
| EP3107566A4 (fr) | 2014-02-18 | 2017-10-11 | Advaxis, Inc. | Immunothérapie multi-cibles dirigée contre un biomarqueur |
| SG11201608820WA (en) | 2014-04-24 | 2016-11-29 | Advaxis Inc | Recombinant listeria vaccine strains and methods of producing the same |
| MA41644A (fr) | 2015-03-03 | 2018-01-09 | Advaxis Inc | Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation |
| CN109310739A (zh) * | 2016-03-31 | 2019-02-05 | 内恩疗法公司 | 新抗原及其使用方法 |
| CN110506107A (zh) | 2016-11-30 | 2019-11-26 | 阿德瓦希斯公司 | 靶向复发性癌症突变的免疫原性组合物及其使用方法 |
| US11179339B2 (en) | 2017-09-19 | 2021-11-23 | Advaxis, Inc. | Compositions and methods for lyophilization of bacteria or listeria strains |
| JP7581048B2 (ja) * | 2018-03-06 | 2024-11-12 | プレシゲン,インコーポレイテッド | ヒトパピローマウイルスワクチンおよびその使用 |
| CN110408634B (zh) * | 2018-04-27 | 2021-08-03 | 苏州若泰医药科技有限公司 | 一种非整合李斯特菌疫苗及抗肿瘤免疫应答方法 |
| EP3826669A2 (fr) | 2018-07-26 | 2021-06-02 | Frame Pharmaceuticals B.V. | Vaccins standard contre le cancer |
| CN111334521B (zh) * | 2018-12-18 | 2022-02-18 | 上海若泰医药科技有限公司 | 一种提高非整合减毒李斯特菌外源抗原蛋白表达的方法 |
| US20220184191A1 (en) * | 2019-03-11 | 2022-06-16 | Evaxion Biotech A/S | Nucleic acid vaccination using neo-epitope encoding constructs |
| WO2021123232A1 (fr) * | 2019-12-18 | 2021-06-24 | Evaxion Biotech Aps | Vaccination par acides nucléiques au moyen de constructions codant pour des néo-épitopes |
| IL297244A (en) * | 2020-04-16 | 2022-12-01 | Parimmune Sas | Schistosoma-derived 28-kilodalton gst proteins for the treatment of vasculitis |
| EP4149506A4 (fr) * | 2020-05-14 | 2024-05-29 | Nutcracker Therapeutics, Inc. | Polynucléotides comprenant une charge utile antigénique |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2724649A1 (fr) * | 2008-05-19 | 2009-11-26 | Anza Therapeutics, Inc. | Compositions comportant un mutant prfa de listeria, et leurs procedes d'utilisation |
| US9017660B2 (en) * | 2009-11-11 | 2015-04-28 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors |
| EP3107566A4 (fr) * | 2014-02-18 | 2017-10-11 | Advaxis, Inc. | Immunothérapie multi-cibles dirigée contre un biomarqueur |
-
2017
- 2017-01-27 WO PCT/US2017/015403 patent/WO2017132547A1/fr not_active Ceased
- 2017-01-27 JP JP2018539059A patent/JP2019503186A/ja active Pending
- 2017-01-27 CN CN201780020675.4A patent/CN108884468A/zh active Pending
- 2017-01-27 AU AU2017211387A patent/AU2017211387A1/en not_active Abandoned
- 2017-01-27 EP EP17744997.2A patent/EP3408395A4/fr not_active Withdrawn
- 2017-01-27 MX MX2018009225A patent/MX2018009225A/es unknown
- 2017-01-27 CA CA3012829A patent/CA3012829A1/fr not_active Abandoned
- 2017-01-27 US US16/073,194 patent/US20190032064A1/en not_active Abandoned
- 2017-01-27 KR KR1020187024523A patent/KR20180100443A/ko not_active Withdrawn
- 2017-01-27 SG SG11201806392XA patent/SG11201806392XA/en unknown
- 2017-01-27 MA MA047398A patent/MA47398A/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3408395A4 (fr) | 2019-12-11 |
| WO2017132547A1 (fr) | 2017-08-03 |
| CA3012829A1 (fr) | 2017-08-03 |
| MX2018009225A (es) | 2019-08-21 |
| KR20180100443A (ko) | 2018-09-10 |
| AU2017211387A1 (en) | 2018-08-16 |
| EP3408395A1 (fr) | 2018-12-05 |
| JP2019503186A (ja) | 2019-02-07 |
| SG11201806392XA (en) | 2018-08-30 |
| US20190032064A1 (en) | 2019-01-31 |
| CN108884468A (zh) | 2018-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA47398A (fr) | Immunothérapie à base de vecteurs d'administration personnalisés et utilisations associées | |
| MA43362A (fr) | Immunothérapie à base de vecteurs d'administration personnalisés, et leurs utilisations | |
| EP3465597A4 (fr) | Vérification d'identité à réalité augmentée | |
| EP3701316A4 (fr) | Système d'affichage à réalité augmentée | |
| EP3607587A4 (fr) | Panneau d'affichage | |
| MA47678A (fr) | Plateforme personnalisée d'identification de peptide immunogène | |
| EP3463405A4 (fr) | Polythérapie à base d'adénovirus et d'immunomodulateurs | |
| EP3479800A4 (fr) | Dispositif d'administration | |
| EP3435978A4 (fr) | Système d'administration | |
| EP3454929A4 (fr) | Dispositif d'entraînement à l'hypoxie | |
| EP3781318A4 (fr) | Émulsifiants et leurs utilisations | |
| EP3551826A4 (fr) | Fenêtres ajustables sur la base d'un emplacement | |
| EP3528507A4 (fr) | Coiffe d'écouteur et écouteur la comportant | |
| EP3441495A4 (fr) | Matériau d'acier inoxydable à base d'austénite | |
| EP3639304A4 (fr) | Transistor à induction statique à ailette latérale | |
| EP3375806A4 (fr) | Copolymère séquencé à base de polyimide et film à base de polyimide le comprenant | |
| EP3494453A4 (fr) | Ensemble carte d'expansion | |
| EP3596102A4 (fr) | Inhibiteurs peptidiques à base de structure ciblant le segment de formation de fibrilles de tau vqiink | |
| EP3506840A4 (fr) | Dispositif d'occlusion aortique temporaire | |
| EP3333237A4 (fr) | Composition adhésive à base d'uréthane | |
| EP3525841A4 (fr) | Micro-dispositif d'administration | |
| EP3635672A4 (fr) | Publicités à réalité augmentée sur des objets | |
| EP3434666A4 (fr) | Dérivé d'arylamine et utilisation correspondante | |
| IT201700050753A1 (it) | Dispositivo indossabile di ausilio contro le cadute | |
| EP3699959A4 (fr) | Écran d'affichage à micro-del et dispositif d'affichage à micro-del |